Home > Boards > US Listed > Biotechs >

Advaxis, Inc. (ADXS)

Add ADXS Price Alert      Hide Sticky   Hide Intro
Moderator: No Moderator jaxstraw, John_Langston
Search This Board:
Last Post: 7/16/2014 8:48:51 PM - Followers: 130 - Board type: Free - Posts Today: 0

Advaxis is a clinical-stage biotechnology company developing the next-generation of immunotherapies for cancer and infectious diseases. The company's immunotherapies are based on a novel platform technology that uses live, bio-engineered bacteria to secrete an antigen/adjuvant fusion protein that redirects the powerful immune response all human beings have to fight off cancer and disease.

The company has more than fifteen distinct constructs in various stages of development, all of which are involved in strategic collaborations with recognized centers of excellence such as the National Cancer Institute, Cancer Research - UK, the Wistar Institute, the University of Pennsylvania, the University of British Columbia, the Karolinska Institutet, and others.

Advaxis' lead construct, ADXS-HPV, is currently in Phase 2 clinical development for recurrent/refractory and advanced cervical cancer, CIN 2/3, and HPV caused head and neck cancers. This important construct was recognized as the Best Therapeutic Vaccine (approved or in development) at the 5th Annual Vaccine Industry Excellence (ViE) Awards by the vaccine industry and the journal Expert Reviews of Vaccines.

The estimated global market for immunotherapies is projected to exceed $37.2B by 2012, with cancer vaccines forecast to grow into an $8B market. Protected by 77 issued and pending patents, Advaxis is extremely well positioned to capitalize on the burgeoning opportunities in the healthcare sector as it advances the development of next-generation treatments for today's most challenging diseases.

Additional Resources

Company Website
Latest Press Releases
Events & Presentation
Fact Sheet

Advaxis Milestones

Report Phase 2 mid-dose CIN 2/3 data Q1 2013
Submit PSA IND Q1 2013
Initiate Phase 1 for PSA Q2 2013
Update Phase 2 cervical cancer data Q2 2013
Complete Phase 2 Cervical Cancer Study Q2 2013
Report Phase 2 high-dose CIN 2/3 data Q2 2013

Advaxis Partners

National Cancer Institute
Gynecologic Oncology Group

Advaxis is collaborating with the GOG to conduct a multi-center, Phase 2 clinical trial of ADXS-HPV, our Lm-LLO based immunotherapy targeted to HPV, in patients with recurrent or refractory cervical cancer who have failed prior cytotoxic therapy. This Phase 2 trial is underwritten by GOG and will be conducted by GOG investigators. This patient population is similar to the patient population in the cervical cancer study being conducted in India as well as the patients in the Phase 1 trial of ADXS-HPV.

Cancer Research UK
Cancer Research UK (CRUK), the UK organization dedicated to cancer research, is conducting a clinical trial to investigate the use of ADXS-HPV, our Lm-LLO based immunotherapy targeted to HPV, for the treatment of head and neck cancer. This Phase 1/2 clinical trial will investigate the safety and efficacy of ADXS-HPV in head and neck cancer patients who have previously failed treatment with surgery, radiotherapy and chemotherapy - alone or in combination. The study is to be conducted at 3 sites in the UK (Aintree Hospital at the University of Liverpool, The Royal Marsden Hospital in London, and Cardiff Hospital at the University of Wales).

Montefiore Medical Center
Advaxis is collaborating with Dr. Chandan Guha at the Albert Einstein College of Medicine and Montefiore Medical Center to develop the ADXS-PSA construct for the treatment of prostate cancer.

Montefiore Medical Center
Advaxis is collaborating with Dr. Chandan Guha at the Albert Einstein College of Medicine and Montefiore Medical Center to develop the ADXS-PSA construct for the treatment of prostate cancer.

Karolinska Institutet
Advaxis is collaborating with the laboratory of Professor Marianne van Hage at the Karolinska Intitutet in Stockholm, Sweden to evaluate the potential of Advaxis immunotherapies to treat and prevent allergies in established scientific models of allergic diseases. Prof. Marianne van Hage's research is focused on further understanding the molecular mechanisms of underlying allergic disease and the function of allergens, and to develop new diagnostic markers and new strategies for vaccination.

University of Pennsylvania School
of Veterinary Medicine

Advaxis is collaborating with Dr. Nicola Mason at the University of Pennsylvania School of Veterinary Medicine to study the ADXS-HER2 construct for the treatment of canine osteosarcoma in large breed companion dogs.

National Cancer Institute Vaccine Section
Advaxis has a Collaborative Research and Development Agreement (CRADA) with the Vaccine Section of the National Cancer Institute for the development of Advaxis immunotherapies. NCI will use different in vitro and in vivo models to elucidate the effect of our immunotherapies on many different types of immune cells. They will also investigate the mechanisms by which they might reduce immune inhibition that protects tumors from immune attack. The work is intended to enhance the anti-tumor effects of Advaxis immunotherapies and alter the tumor microenvironment, enabling them to be used with other methods of cancer treatment.

Wistar Institute
Advaxis is collaborating with the Wistar Institute to explore the potential of FAP as a target for immune attack and as the basis for the development of an Advaxis immunotherapy. Therapeutically targeting FAP (fibroblast activation protein) might significantly reduce tumor growth, as it has in some mouse studies.

Wistar Institute
Advaxis is collaborating with the Wistar Institute to explore the potential of FAP as a target for immune attack and as the basis for the development of an Advaxis immunotherapy. Therapeutically targeting FAP (fibroblast activation protein) might significantly reduce tumor growth, as it has in some mouse studies.

University of British Columbia
Advaxis is collaborating with the laboratory of Dr. Tobias Kollmann at the University of British Columbia to develop Advaxis immunotherapies for the treatment of infectious disease and to develop new dosage forms. Dr. Kollmann is an immunologist and neonatal vaccinologist who has published extensively on the use of Listeria immunotherapies as potential therapeutic agents for the treatment of childhood diseases. Dr. Kollmann will use our proprietary immunotherapy vectors for the development of novel infectious disease applications.

Management Team

Thomas A. Moore, Chairman / CEO

On December 15, 2006, Thomas Moore was named our Chairman and Chief Executive Officer. He also serves as Chairman of the Board of Directors of Mayan Pigments, Inc., which has developed and patented Mayan pigment technology. Previously, from June 2002 to June 2004 Mr. Moore was President and Chief Executive Officer of Biopure Corporation, a developer of oxygen therapeutics that are intravenously administered to deliver oxygen to the body's tissues. From 1996 to November 2000 he was President and Chief Executive Officer of Nelson Communications. Previously, Mr. Moore had a 23-year career with the Procter & Gamble Company in multiple managerial positions, including President of Health Care Products where he was responsible for prescription and over-the-counter medications worldwide, and group vice president of the Procter & Gamble Company.

Mark J. Rosenblum, CFO, Secretary, Senior VP

Mr. Rosenblum joined Advaxis in January 2010 as Chief Financial Officer, Senior Vice President, and Secretay. Prior to Advaxis, Mr. Rosenblum managed financial operations on behalf of an early stage publicly traded biotech headquartered in Dallas, Texas. From August 1985 through June 2003, he served in various financial leadership positions at Wellman, Inc., a chemical and recycling company. As a corporate controller for Wellman, he participated in the company's transition from a $125 million privately held plastic recycling company into a publicly traded corporation with an excess of $400 million in revenue. In 1989, Wellman acquired the polyester assets of a former Celanese Corporation spin-off for over $550 million. Mr. Rosenbum became Vice President, Corporate Controller. Following that acquisition, the company reached almost $1 billion in revenue. In 1996, he was promoted to the position of Chief Accounting Officer, serving in that role until 2003. Mr. Rosenblum's career has afforded him the opportunity to serve as a hands-on financial leader, participating in Wellman's active M&A strategy, and managing the divestures for Wellman while the company navigated both the declining US textile business and the growing PET plastics packaging business. Before joining Wellman, Mark was a plant financial controller for Celanese Corp. Prior to his chemical industry experience, Mr. Rosenblum was in the public accounting profession, beginning his career with Haskins and Sells (now Deloitte and Touche) in their New York office in 1977. Mr. Rosenblum holds both a BS and Masters of Accountancy from the University of South Carolina and has been a CPA for over 30 years.

John Rothman, Ph.D., Executive VP of Science & Operations

Dr. John Rothman is currently EVP of Science & Operations at Advaxis Inc,. He was Director of Clinical Drug Development, and then Sr. Director of all of Roche's data collection, analysis, and report writing. He was a senior scientist at Hoffmann-LaRoche working with recombinant agents provided by Genentech, where his work with interferon-a (Roferon-A) in AIDS related Kaposi's sarcoma became the basis for the first BLA. Dr. Rothman was a member of the first clinical group to develop genetically recombinant pharmaceutical agents and test them in human disease at Schering Plough using Biogen's a-interferon, where was the monitor for the first clinical trial in AIDS in 1984. He studied at the Department of Pharmacology at the Tulane University School of Medicine in the laboratory of Dr. Louis Ignarro (Nobel Prize; Medicine, 1998) and conducted his dissertation research at the New Orleans V.A. Hospital laboratory of Dr. Andrew Schally (Nobel Prize; Medicine, 1977). He has developed many different pharmaceutical agents in many disciplines including infectious disease, gastroenterology, neurology, oncology and virology.

Robert Petit, Ph.D., VP Clinical Operations & Medical Affairs

Dr. Robert Petit has 23 years of experience in all medical and scientific aspects of pharmaceutical development. He has led programs in discovery, translational development and intellectual property development and has designed and conducted U.S. and international clinical evaluation programs from phase I to IV. Dr. Petit joins Advaxis from Bristol Myers Squibb where he was the U.S. Medical Strategy Lead for the Ipilimumab program, director of Medical Strategy for New Oncology Products, and director of Global Clinical Research. Prior to joining Bristol Myers-Squibb, Robert served as vice president of Clinical Development at MGI Pharma and also at Aesgen Inc. His scientific focus has been to develop immunologic based therapies with a particular emphasis on immunologic oncology treatment. Robert has had significant FDA experience and has contributed to five NDA/BLA filings. Dr. Petit has a Doctorate from the Ohio State University College of Medicine and a B.S. from Indiana State University.


  • 1D
  • 1M
  • 2M
  • 3M
  • 6M
  • 1Y
  • 2Y
  • 3Y
  • 5Y
Current Price
Bid Ask Day's Range
#3134   Confidential SEC filing Zeratul 07/16/14 08:48:51 PM
#3133   Therelase. Tltff. Very promissing. itsallgood11 07/11/14 06:12:06 PM
#3132   It looks as though all the shareholders are inveterate 07/11/14 02:28:26 PM
#3131   I wish I had some but I am jaxstraw 07/10/14 08:51:56 AM
#3130   Jax, do you see any positive outcome from inveterate 07/09/14 10:30:56 PM
#3129   http://stockcharts.com/c-sc/sc?s=ADXS&p=D&b=5&g=0&i=t77258732956&r=1402181512881 jaxstraw 07/07/14 09:14:58 AM
#3128   KANSAS CITY, Kan., July 2, 2014 /PRNewswire/ -- jaxstraw 07/07/14 09:13:57 AM
#3127   http://ih.advfn.com/p.php?pid=nmona&article=62820696&symbol=ADXS jaxstraw 07/07/14 09:13:13 AM
#3126   On July 2, 2014, Advaxis, Inc. (the “Company”) jaxstraw 07/07/14 09:12:51 AM
#3125   http://www.pharmpro.com/videos/2014/06/new-vaccine-may-give-dogs-second-chance steadykickin 06/27/14 01:05:22 PM
#3124   Great news piece on Advaxis vaccine for dogs. http://newyork.cbslocal.com/vide James salmon 06/26/14 12:57:41 AM
#3123   ADXS: Looking like a move is coming! rayinbrooklyn65 06/07/14 06:52:30 PM
#3122   Chart: I-Hub's Most Actives: ADXS rayinbrooklyn65 06/07/14 06:51:47 PM
#3121   I sure wish they had this available Wildbilly 06/06/14 07:54:29 AM
#3120   breaking resistance, could see the 4.00's on a heavyJ 06/03/14 03:00:59 PM
#3119   http://seekingalpha.com/article/2249433-advaxis-mirrors-imclone-systems-prior-to John_Langston 06/03/14 06:14:21 AM
#3118   Morning, Inveterate. terry hallinan 05/30/14 09:04:58 AM
#3117   Why do you say that the Advaxis technology inveterate 05/29/14 08:17:57 PM
#3116   If we can ever get past the proxy Big Barnie 05/29/14 07:29:08 PM
#3115   Has anyone else seen this, will prove to James salmon 05/29/14 03:52:08 PM
#3114   I would like to see a nice bounce John_Langston 05/26/14 01:41:20 PM
#3113   Weekly Chart: ADXS -- Monday, May 26, 2014 rayinbrooklyn65 05/26/14 01:33:37 PM
#3112   I see the pattern now but who would John_Langston 05/25/14 04:07:19 PM
#3111   These "channel trading" stocks are my favorite! rayinbrooklyn65 05/25/14 03:54:16 PM
#3110   LOL; I bought at $3.03 after the huge John_Langston 05/25/14 03:29:57 PM
#3109   I agree! These types of tickers are rayinbrooklyn65 05/25/14 03:21:17 PM
#3108   This is a great flipping stock; buy at John_Langston 05/25/14 09:55:30 AM
#3107   Stock Charts: ADXS rayinbrooklyn65 05/24/14 07:19:21 PM
#3106   Barnie, have been away for the last week, James salmon 05/21/14 10:16:39 PM
#3105   A question for James Salmon Big Barnie 05/21/14 02:16:38 PM
#3104   'Dallas Buyers Club' Experimental Drug Bill Passed rmarc 05/17/14 12:58:35 PM
#3103   ASCO abstract 2014 http://abstracts.asco.org/144/AbstView_144_128776.html xoc 05/14/14 09:55:49 PM
#3102   Poster abstracts ASCO meeting are available 5/14 @ xoc 05/10/14 10:01:26 PM
#3101   It seems to me that it will be Big Barnie 05/08/14 11:57:54 AM
#3100   Just keep in mind, according to company presentation, James salmon 05/08/14 09:53:28 AM
#3099   Jaxstraw I think your theory about old financing deals Donjayouworry 05/03/14 06:38:50 PM
#3098   Good luck to us. John_Langston 05/01/14 08:15:12 PM
#3097   5 yrs. I have traded it all at jaxstraw 05/01/14 07:49:57 PM
#3096   How long have you been following ADXS; I John_Langston 05/01/14 07:39:57 PM
#3095   You're guess is as good as mine....and my jaxstraw 05/01/14 07:34:26 PM
#3094   Then why was it recently trading at $6.00 John_Langston 05/01/14 07:33:41 PM
#3093   I personally think it is a giant leap forward. jaxstraw 05/01/14 07:32:28 PM
#3092   $42mm ? They have no product to market jaxstraw 05/01/14 07:30:07 PM
#3091   How do you feel about today's news? John_Langston 05/01/14 07:30:00 PM
#3090   Wrong guy to ask really...not my forte. jaxstraw 05/01/14 07:28:28 PM
#3089   Is Advaxis not worth more than $42 Million? John_Langston 05/01/14 07:27:19 PM
#3088   Correction on the OS from the most recent 10Q... jaxstraw 05/01/14 07:22:56 PM
#3087   What do you think Advaxis is worth? John_Langston 05/01/14 07:22:29 PM
#3086   25mm jaxstraw 05/01/14 07:18:22 PM
#3085   How many shares are AS? John_Langston 05/01/14 06:40:43 PM